Under the agreement, Quintiles' commercialization unit, Innovex, will provide a dedicated sales force of 150 cardiovascular-trained representatives who, in combination with Kos Pharmaceuticals' force of 300 representatives, will commercialize Advicor and Niaspan for two years.

Quintiles' strategic investment group, PharmaBio Development, has entered into a five-year commission agreement with Kos based upon the commercialization program for Advicor and Niaspan. Quintiles expects this transaction to generate operating profit throughout the term of the agreement.

Ron Wooten, president, PharmaBio Development said, "Our agreement with Kos is another example of Quintiles' ability to structure strategic and financial solutions for its customers."

Richard Johnson, M.D., chief executive officer, Quintiles Commercialization North America, said, "The addition of the Innovex sales force helps Kos Pharmaceuticals expand their promotional message to a wider range of physicians. Innovex was able to deploy a team of experienced sales representatives to meet Kos' objectives for the launch of Advicor."

About Quintiles Transnational, PharmaBio Development and Innovex
Quintiles Transnational Corp. is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles Transnational is a member of the S&P 500 and Fortune 1000. For more information visit the company's Web site at www.quintiles.com.

PharmaBio Development is the corporate ventures group of Quintiles Transnational Corp. that is dedicated to innovative partnering solutions for pharmaceutical and biotech companies.

Innovex is the world's leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotech and medical device products. These services include contract sales services, strategic marketing solutions, customized information technologies and health management services. For more information, visit www.innovex.com.

Information in this press release contains "forward-looking statements" regarding Quintiles that involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the risk that the market for our products and services will not grow as we expect, the risk that PharmaBio transactions will not generate revenues or profit at the rate or levels we anticipate, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.